Company: BLLN
Filing Date: 2025-06-20
Form Type: DRS
Source: 0000950123-25-006095
Chunk: 193

Company: BillionToOne, Inc.
Filing Date: 2025-06-20
Form: DRS
Chunk 193
---
 is lower than the reimbursement amounts suggested by the codes. We maintain a systematic approach to appeals for denied claims, with variable success rates depending on the payor and reason for denial. Our appeals process is supported by our internal reimbursement team, who analyze denial patterns and optimize appeal strategies accordingly. Moreover, as our test volume increases, we believe this will improve our ability to secure network contracts with more commercial insurers, which should decrease claim denials and increase ASPs. In addition, we have built a robust revenue cycle management infrastructure to optimize reimbursement for our tests, which includes internal and external resources, as well as AI-basedautomation for processing payor communications and streamlining claims management. Patient access and financial assistance We provide comprehensive patient support services, including pre-authorizationsupport where required by payors, patient-focused education about potential financial responsibilities and personalized financial assistance for patients who indicate an inability to afford out of pocket charges. Reimbursement expansion strategy We are actively generating additional clinical validity and utility evidence to expand coverage of our tests. For our prenatal products, we continue to build evidence demonstrating improved outcomes and cost-effectiveness compared to traditional approaches. In oncology, our NORTH study and other ongoing clinical studies aim to demonstrate the clinical utility of Northstar Response in early therapy response assessment across multiple cancer types and treatment modalities. In addition, inclusion in clinical practice guidelines is a key element of our reimbursement strategy. Recent ACOG practice advisory changes have cited our publications in support of new approaches to testing. Additionally, inclusion of our specific tests, such as sgNIPT, or broader adoption of testing categories like 22q11.2 microdeletion screening in ACOG guidelines could significantly increase coverage and ASPs. Moreover, our publication strategy prioritizes studies that address key questions relevant to clinical guideline development. We continuously pursue strategic initiatives to enhance our reimbursement landscape, including:

| • |     | Expansion of in-network coverage. As we increase test volumes and publish                        
 additional evidence, we expect to secure additional in-network contracts with commercial payors. |

| • |     | Medicare coverage expansion. We are working toward Medicare coverage for Northstar Response, beginning with 
 applications in immunotherapy response monitoring where the clinical utility is most established.           |

| • |     | Clinical guideline incorporation. We actively engage with professional societies to support the inclusion of our 
 testing methodologies in clinical practice guidelines.                                                           |

| • |     | Test menu optimization. We evaluate reimbursement potential when developing new tests or expanding existing test 
 menus to ensure alignment with payor policies.                                                                   |